Small, mid-sized and large biotech companies discuss major hurdles they encountered and how a customer-centric CDMO partnership can help overcome these, dismissing the idea of one-size-fits-all.
Long Form - A recent survey of more than 50 small, mid-sized and large biopharmaceutical companies worldwide, we shed light on the key reasons why biotechs outsource their early biologic development and manufacturing to a CDMO. Here we offer perspectives on what we heard from respondents. We will discuss major hurdles biotechs mentioned and how a customer-centric CDMO partnership can help overcome these, dismissing the idea of one-size-fits-all.
Learn more about:
- Top reasons to outsource to a CDMO
- Overcoming hurdles with a CDMO partnership
- What early-stage biotechs should look for in a CDMO